TY - JOUR KW - Cohort Studies KW - Humans KW - Longitudinal Studies KW - *Myasthenia Gravis/drug therapy/epidemiology KW - Outcome Assessment, Health Care KW - Retrospective Studies KW - Burden of illness KW - England KW - Gprd KW - Myasthenia gravis KW - Myasthenic crisis KW - Refractory AU - L. Harris AU - S. Graham AU - S. MacLachlan AU - A. Exuzides AU - S. Jacob AD - Biohaven Pharmaceuticals, 215 Church Street, New Haven, CT, 06510, USA. , The Ark, 201 Talgarth Road, London, W6 8DL, UK. , 450 Sansome Street, Suite 650, San Francisco, CA, 94111, USA. Department of Neurology and Centre for Rare Diseases, Institute of Immunology and Imunotherapy, University Hospitals Birmingham and University of Birmingham, Mindelsohn Way, Edgbaston, Birmingham, B15 2GW, UK. Saiju.Jacob@uhb.nhs.uk. AN - 35534810 BT - BMC Neurol C2 - PMC9082838 DO - 10.1186/s12883-022-02692-4 DP - NLM ET - 2022/05/10 LA - eng M1 - 1 N1 - 1471-2377 Harris, Linda Graham, Sophie MacLachlan, Sharon Exuzides, Alex Jacob, Saiju Journal Article BMC Neurol. 2022 May 9;22(1):172. doi: 10.1186/s12883-022-02692-4. PY - 2022 SN - 1471-2377 EP - 172 T2 - BMC Neurol TI - A retrospective longitudinal cohort study of the clinical burden in myasthenia gravis VL - 22 ER -